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Is Plasma Pentadecanoic Acid a Reasonable Biomarker
of Dairy Consumption?
Luc Djousse, MD, ScD
D espite advances in biomedical research and clinicalmedicine, the burden of cardiovascular disease (CVD)
remains extremely high.1 This underscores the importance of
primary prevention and the search for novel therapeutic
strategies. Modiﬁable lifestyle factors, including dietary
habits, play a critical role in the primary and secondary
prevention of CVD.2–4 Among food groups, dairy products
have been studied for many years partly due to concerns that
saturated fat contained in dairy foods may raise low-density
lipoprotein cholesterol, a major risk factor for CVD. However,
reported effects of saturated fats and dairy products including
milk, butter, cheese, yoghurt, etc, on CVD risk have been
inconsistent.5–11
Such inconsistency could be partly attributable to the type
of fatty acids in dairy products, the amount of fat per ﬁxed
quantity in dairy products (ie, fat-free milk versus reduced--
fat/whole milk), and difﬁculties in accurate assessment of
dairy consumption in population science. Of note is that in
large epidemiologic studies and randomized trials, dietary
assessment is mostly completed via food frequency ques-
tionnaires, food diary for a short-term period, or 24-hour
dietary recall to minimize costs. More importantly, several
food groups lack reliable and valid biomarkers that can be
used to assess their intake. These limitations could introduce
bias in studies assessing the relation or effects of dairy
products with CVD (due to exposure misclassiﬁcation, erro-
neous or missing values).
In this issue of JAHA, Otto et al12 address one of the above
gaps by examining whether plasma phospholipid fatty acids
such as pentadecanoic acid (15:0), myristic acid (14:0), and
trans-palmitoleic acid (t16:1n7) could serve as biomarkers for
dairy intake and the association of those fatty acids with CVD
risk in about 2800 US adult men and women from the
Multi-Ethnic Study of Atherosclerosis (MESA). The authors
found that plasma phospholipid pentadecanoic acid was
positively correlated with self-reported total dairy intake
(Spearman correlation coefﬁcient of 0.22), regular cheese
(r=0.20), whole-fat dairy (r=0.16), low-fat dairy (r=0.17), and
butter (r=0.13). Each standard deviation of pentadecanoic acid
was associated with 19% lower risk of CVD (95% CI: 2% to 32%)
and 26% lower risk of coronary heart disease (95% CI: 8% to
40%) in multivariable adjusted models. Plasma phospholipid
myristic acid was weakly correlated with self-reported total
dairy (r=0.14), whereas trans-palmitoleic acid was not corre-
lated with self-reported total dairy (r=0.07). Lastly, in multi-
variable analyses, there was no meaningful association of
either plasma phospholipid myristic acid or trans-palmitoleic
acid with CVD risk. These data suggest that plasma phospho-
lipid pentadecanoic acid could be a reasonable biomarker of
dairy intake. In addition, current data raise the following
question: What implications do current ﬁndings underscore for
the scientiﬁc community and translational medicine?
It is important to acknowledge some weaknesses inherent
to the current study. Although plasma levels of 15:0 were
measured using a reproducible and valid method, self--
reported dairy intake used to estimate Spearman correlation
coefﬁcients is far from optimal due to potential recall bias. A
long-term intervention with known quantity and quality of
dairy product(s) would be ideal to estimate the true correla-
tion between plasma 15:0 and consumed dairy product(s).
Concentration of plasma 15:0 is relatively low (median below
1% of total fatty acids), suggesting that small measurement
errors could have a larger impact on reported values. A large
coefﬁcient of variation (14.5%) for pentadecanoic acid is
consistent with the above conjecture. In addition, a wide
range of Spearman correlation of plasma 15:0 with various
dairy products (ranging from 0.05 for 2% milk to 0.20 for
regular cheese) suggests that content of 15:0 may vary
across individual dairy products. Alternatively, reporting error
may vary by types of dairy products. Given a diversity of
individual dietary patterns, it is important to recognize that
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plasma phospholipid 15:0 would then vary according to the
type of dairy foods consumed. Lastly, despite an observed
association of plasma 15:0 with CVD risk, it is important to
emphasize that 15:0 cannot be singled out as a causal
nutrient responsible for the overall effect of dairy products.
Dairy products are a good source of other nutrients known to
exert CVD beneﬁts including vitamin D and calcium.13,14
Furthermore, people consume dairy products as part of
overall dietary patterns, underscoring the importance of
nutrient/nutrient, nutrient/drug, or nutrient/other lifestyle
interactions on CVD risk. The contribution of such interaction
cannot be estimated from current results.
Nonetheless, current ﬁndings are consistent with previous
data supporting the role of plasma 15:0 as a biomarker of dairy
intake.5,15–17 In older men aged >70 years, phospholipid 15:0
was positively correlated with total dairy assessed by 7-day
records (r=0.34).17 A similar correlation was observed in the
Nurses’ Health Study (r=0.29).5 Inverse relation of plasma
15:0 with CVD is consistent with the notion that dairy products
may confer cardiovascular beneﬁts.9,11,18,19 However, it
remains important for consumers to consider their overall
dietary patterns, which should favor a healthy diet that is rich
in fruits, vegetables, and whole grains, but low in sodium, red
meats, sugar sweetened beverages, trans fat, etc.20
Future endeavors are necessary to conﬁrm the utility of
plasma 15:0 as a biomarker of dairy intake using better
designs to assess dairy intake. Ideal biomarkers should be
quantiﬁable with a reasonable coefﬁcient of variation and their
blood levels should not be inﬂuenced by endogenous bio-
synthesis. Lastly, ideal biomarkers should be cost-effective to
allow for usage in large epidemiologic studies or trials and their
blood levels should increase upon external supplementation.
In summary, there is a growing body of evidence in support
of potential biomarkers for dairy intake, especially penta-
decanoic acid. However, additional work from randomized
trials where subjects are fed speciﬁc amounts and types of
dairy products is needed before making general recommen-
dations for the use of pentadecanoic acid as valid biomarker
of dairy intake.
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